Related Experiment Video
Updated: Oct 3, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Vascular calcification: pathogenic mechanisms, signaling crosstalk and translational therapeutics
Rui Hua1,2,3,4, Bao Qiao1,2,3,4, Xuehao Liu1,2,3,4
1Department of Emergency and Chest Pain Center, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Abstract:
Vascular calcification (VC) is a multifactorial pathological process characterized by ectopic deposition of hydroxyapatite in the arterial wall, which is closely associated with increased cardiovascular morbidity and mortality. This review provides a comprehensive synthesis of current insights into the pathogenesis of VC, emphasizing its nature as a dynamically regulated process driven by intricate crosstalk among diverse molecular mechanisms, signaling cascades, and pathological pathways. Under specific pathological stimuli, this intricate regulatory network disrupts the homeostatic balance between pro-calcific and anti-calcific mechanisms. Key drivers of VC include the phenotypic transformation of vascular smooth muscle cells (VSMCs), endothelial-to-mesenchymal transition (EndMT), inflammation, oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, and various forms of programmed cell death. The transcription factor RUNX2 serves as a central regulator, integrating signals from pathways such as WNT/β-catenin, BMP/Smad, PI3K/AKT, MAPK, AMPK, NF-κB, Notch, and Rho/ROCK. Furthermore, emerging evidence highlights the critical regulatory roles of epigenetic mechanisms, including posttranslational modifications (PTMs) and noncoding RNAs (lncRNAs, miRNAs, circRNAs). Given the complexity of VC, we critically evaluate the efficacy and safety of various pharmacological interventions from clinical trials, including bisphosphonates (BPs), calcimimetics, phosphate binders, dipeptidyl peptidase-4 inhibitor (DPP4i), SNF472, sodium-glucose cotransporter 2 inhibitors (SGLT2i), statins, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), sodium thiosulfate, and vitamins K and D, while also discussing potential endogenous molecules and natural compounds. A deep understanding of these interconnected molecular networks is essential for developing precision therapies to mitigate VC and VC-related cardiovascular complications.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Non-Canonical Wnt Signaling Pathways
Non-Canonical Wnt Signaling Pathways
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Canonical Wnt Signaling Pathway
Regulation of Angiogenesis and Blood Supply

